chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was vaccinated in school-based mass clinic setting by Public Health. She reported feeling well prior to being vaccinated and tolerated vaccine administration well. Per review of consent form completed by child's mother, child does not have any allergies to medications, food, a vaccine component or latex. She has not had any serious reaction to vaccines in the past, and she does not have any brain or other nervous systems problems or history of problems. Patient's mom phoned the school nurse the following morning (11/17/17). School nurse in turn phoned Public Health to discuss. Patient's mom reports that child started with symptoms last night (day of vaccination). States that left arm was red and swollen, also itchy. She reports that the redness is approximately soft-ball sized. Mom had been in touch with the child's doctor who advised on home care remedies. It should be noted that child had a very similar reaction to the vaccine last year (2016) given also by Public Health in the school-based mass clinic setting. Mom stated to school nurse that next year she is going to request that child receive a preservative-free vaccine. Many attempts were made by PH to get in contact with child's mother to explain that child did receive preservative-free vaccine from PH last year and this year. Unable to connect with patient's mom to discuss. Followed up with child's school nurse who reported that she will explain to child's mother and will advise mom to complete the consent form next year indicating that child has had a reaction to the vaccine in the past and may want to consider having the vaccine administered by her HCP.
burning sensation; his right upper thigh start to pain; first dose/ around the end of 2019 or early 2020 / second dose around the beginning of 2021; This case was reported by a consumer via call center representative and described the occurrence of burning sensation in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose at the end of 2019 or early 2020).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, immediately after receiving Shingrix, the patient experienced burning sensation, pain in thigh and drug dose administration interval too long. On an unknown date, the outcome of the burning sensation and pain in thigh were not recovered/not resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the burning sensation and pain in thigh to be related to Shingrix.  Additional information was provided as follows: The case was reported by patient's wife. The patient received the 2nd dose of Shingrix at the beginning of 2021, later than the recommended schedule, which led to lengthening of vaccination schedule. The reporter mentioned that, the patient received 2nd dose may be in his left arm and his right upper thigh started to pain with burning sensation. The reporter consented to follow up.
Stomach pain. Diarrhea. Headaches. Nausea. Wheezing. Troubling breathing. Mucus. pain in lungs when breathing.
An hour and a half after the vaccine pt. experienced vomitting, developed body aches, developed an "egg" on the right deltoid, red and hot. Diarrhea developed two days later, loss of appetite. Tuesday after the vaccine on Friday patient started experiencing visual hallucinations, felt angry. Only one episode. (Saw three people and got her gun but then didn't see them again.)
Rash at the site of injection, raised & firm to the touch, warm to the touch, itchy at times from approximately 34 hours after the injection, still currently in effect approximately 72 hours after injection.  Headache starting approximately 8 hours after injection, lasting for approximately 24 hours.  Fatigue starting approximately 8 hours after injection, lasting for approximately 24 hours.
17 year old received the vaccine; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old received the vaccine) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old received the vaccine). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old received the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the event was not applicable.  Treatment details not provided. Concomitant medications were not reported.
Deep fatigue, full-body aches and chills, low grade fever, pain at injection site
pt recvd vax 27OCT93 & 29OCT93 devel a h/a, nasal stuffiness hwich were treated w/Ornade & Ceftin; 8NOV93 & devel paralysis on lt side of face; MD dx Bell's Palsy & felt this was related to flu vax; pt is undergoind physical therapy & elec;
15 to 20 minutes after administration of the vaccine, consumer's mouth and tongue began to swell; 15 to 20 minutes after administration of the vaccine, consumer's mouth and tongue began to swell; consumer broke out in hives; This spontaneous report was received from a patient's grandmother and refers to a male patient of unknown age. There was no information about his concurrent conditions, concomitant therapies or medical history provided. On an unknown date (also reported as years ago), the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (formulation, strength, dose, frequency, route of administration, lot # and expiration date were not reported) for prophylaxis.  On the same date, 15 to 20 minutes after administration of the vaccine, the patient's mouth and tongue began to swell and he broke out in hives. On an unknown date, he sought medical attention. The unspecified injection and unspecified medication were given to treat the reaction. The outcome of the events was not reported. The causality assessment between the events and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was not provided.
Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash Generalized-Medium, Additional Details: 45 minutes after patient recieved the vaccine , she came back complaining aboout generalized mild to mederate rash and redness specially in the upper extremeties. advised patient that a call to 911 will be required and possible emergency visit. patient approved , i called 911 and while on the phone briefing the operator i was advised not to give the paient any medications or food or drinks and the emt will be on the way now
Diarrhea for several days, Swollen face, shooting nerve pains in face and head, face painful to the touch, as if nerves inflamed. Doctor suspected shingles, but no blisters appeared. Pain stopped after five days. Swelling lasted a couple of weeks.  Irritated nerve sensation in trunk persists,
Extreme Fatigue, slept, woke up drenched in sweat resembling fever breaking.  Worst symptoms lasted approximately 6 hours.  Slept well all night.  No symptoms today.
This is a 25-year-old otherwise healthy female banker who flew to see her fiance on Saturday and today 2/3/14 at 9 a.m. after taking some Dramamine for a whale watching trip, had the sudden onset of bilateral arm numbness. She presented to our emergency room here at approximately 11 a.m. and soon after had numbness in all extremities. This numbness was not associated with dysesthesias, paresthesias, skin changes, or other symptoms, but by mid afternoon was associated with flaccid quadriparesis of all extremities. She began to have her minimum inspiratory and expiratory pressures monitored in the emergency room and they were never less than 60. In terms of the associated symptoms, she denies any headaches or vision changes, or hearing changes, dysphagia, odynophagia, neck stiffness, fevers, chills, nausea, vomiting, diarrhea, or recent illness. Specifically, she has not had a cold or flu symptoms this entire winter season. She has recently received the last course of her HPV vaccine, the third dose in January 2014. Although she did take ibuprofen 200 mg x1 shortly before the onset of symptoms, she has not been taking any other analgesics and she has no possible exposures to Botox or botulinum toxin. She denies any recent immunizations other than she finished up in January the vaccine to prevent the HPV. The patient reported that symptoms all came on rather quickly within an hour of presentation. The patient reports no history of known vasculitis, no history of previous stroke, and no history of multiple sclerosis. The patient is unclear as to what exactly precipitated this at this time. Patient treated for Guillain Barre with plasmapheresis.
Patient stated on the phone that the arm was swollen, itchy and 2 small what looks like blisters.
the patient was accidentaly administered a dose of proquad instead of a dose of MMR II; the patient was accidentaly administered a dose of proquad instead of a dose of MMR II; On an unspecified date in June 2020 the patient was found to have a negative titer; This spontaneous report was received from a nurse referring to a 21-year-old female patient.  The patient did not have any pertinent medical history. The patient's drugs reactions/allergies were unknown. The patient's concomitant medications included unspecified birth control medications.  On an unknown dates, the patient was vaccinated with series of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (dose, anatomical location, route, lot # and expiration date were unknown) for prophylaxis (reported as "prevention of measles, mumps and rubella"). On an unknown date in June 2020, the patient was found to have a negative titer (antibody test negative). On 23-JUN-2020, the patient came into office for administration of a measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) booster dose. On same day, the patient was accidentally administered with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (dose, anatomical location, route, lot # and expiration date were unknown) for prophylaxis, instead of a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (interchange of vaccine products, wrong product administered). It was reported that the administration of the dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) was not related to product confusion caused by the packaging. No product quality complaint (PQC) involved. The outcome of antibody test negative was unknown. The causality assessment was not provided.
This spontaneous report as received from a certified medical assistant refers to a 1 year old patient of unknown gender. The patient's concurrent condition, medical history or concomitant medications were not reported. On 11-AUG-2015, the patient was inadvertently vaccinated with PNEUMOVAX 23 (dose, lot #, expiration date and route of administration not reported) instead of PREVNAR 13. No adverse effects were reported. Additional information has been requested.
Pt received injection Thursday and came back to clinic Friday afternoon with moderate size swelling and soreness at injection site of varicella redden and swollen the size of golf ball around raised 4-5 mm and warm.  By next Tuesday (8/7/12) swelling down and left arm normal.  Patient took ibuprofen and used cold packs cold packs on swollen arm.
This spontaneous report as received from a medical assistant refers to a 19 year old patient of unknown gender. The patient's drug allergies and pertinent medical history was not reported. On 13-JUN-2014 the patient was vaccinated with the first dose of GARDASIL (dose, frequency and route of administration were not reported) (lot # J009788, expiry date: 17-MAR-2016) which was stored improperly. No adverse effects were noted. No product quality complaint was reported for GARDASIL. This case is linked to 1407USA010956, 1407USA012902, 1407USA012903, 1407USA012904, 1407USA012905, 1407USA012906, 1407USA012907, 1407USA012908, 1407USA012909, 1407JSA012910, 1407USA012911, 1407USA012912, 1407USA012913, 1407USA012914, 1407USA012915, 1407USA012916, 1407USA012918, 1407uSA012919, 1407USA012920, 1407USA012921, 1407USA012922, 1407USA012923, 1407USA012924, 1407USA012925, 1407USA021926, 1407USA012927, 1407USA012928, 1407USA012929, 1407USA012930, 1407USA012931, 1407USA012932, 1407USA012933, 1407USA012934, 1407USA012935, 1407USA012936, 1407USA012937, 1407USA012938, 1407USA012939, 1407USA012940, 1407USA012941, 1407USA012949, 1407USA012950, 1407USA012951, 1407USA012952, 1407USA012953, 1407USA021954, 1407USA012955, 1407USA012956, 1407USA012957, 1407USA012958, 1407USA012959, 1407USA012960, 1407USA012961, 1407USA012962, 1407USA012963, 1407USA012964, 1407USA012965, 1407USA012966, 1407USA012967, 1407USA021968, 1407USA012969, 1407USA012970, 1407USA012971, 1407USA012972, 1407USA012973, 1407USA012974, 1407USA012975, 1407USA012976, 1407USA012977, 1407USA012978, 1407USA012979, 1407USA012980, 1407USA012981, 1407USA012982, 1407USA012983, 1407USA012984, 1407USA012985, 1407USA012986, 1407USA012987, 1407USA012988, 1407USA012989, 1407USA012997, 1407USA012998, 1407USA012999, 1407USA013000, 1407USA013013 and 1407USA013014 (same reporter link). Additional information has been requested.
A report has been received from a Health Professional concerning a 4 year old, Male subject, who had been receiving FLUMIST QUARDIVALENT (intranasal). FLUMIST QUARDIVALENT started on 14-Jan-2014. It was reported by Health Professional that accidentally gave an expired dose of FLUMIST on 14-Jan-2014. The outcome of the event of gave an expired dose is unknown. The report was considered to be non-serious.
Fainted, nausea, red in face then pale - called 911 per protocol - check BP over 30 min. time.
Pt. states she has pain in her left shoulder then switches to right shoulder and also had gone down the left hip and left ankle. Pt. states she had not had these issues previously.
Information has been received from a Licensed Practical Nurse concerning a 6 months old female patient who on 13-OCT-2010 was vaccinated with the first dose of ROTATEQ (lot number unknown). The nurse stated that the child threw up after administration of the ROTATEQ. At the time of report, the patient's outcome was unknown. The patient sought unspecified medical attention. Additional information has been requested.
Tingling in my throat and tongue, Nausea, Diarrhea, Hives, My whole body was tingling and itchy, Pain in my left leg Lymph nodes under both armpits.
Depression, Headache, Back pain, Neck pain, Paraesthesia, Arthralgia, Influenza like illness, Fatigue, Visual disturbance, Medication error. This report described the occurrence of depression in a female patient who received Lyme disease vaccine recombinant OspA (LYMErix) for prophylaxis. This report was received as part of litigation proceedings, and has not been verified by a physician or other health care professional. The patient received injections of LYMErix on 29 June 1999, 30 July 1999 and 26 July 2001 "according to the client." This represents a 0,1, and 25 months schedule rather than the reccomended schedule of 0,1, and 12 months. On 03 September 2003, the patient's attorney alleged that the patient "suffered headaches, soreness of her back and neck, tingling, joint pain, flu-like symptoms, fatigue, vision problems and depression. The onset of her symptoms is not clear at this time." Treatment and outcomes of the alleged events were not reported.
Anxiety thanks to crowds and fleeting initial dis-organization at  the vaccine facility.  Sore arm the evening of the injection and the next day.  Joint/muscle aches and pains nights the 10th and 11th that interrupted sleep; took acetaminophen. Aches during the day and tired the 11th, 12th and 13th (so far). Strange taste in mouth, upset stomach 12th and 13th (so far).  Not looking forward to second dose though happy to have started process.
Lip tingling, Flushed, dizziness, leg heaviness Tx: none. Vitals taken, o/c home; improved on o/c Allergy review recommended  -observed for 1 hr and 20 min -dose 2 given 1/11/2021
Bone pain; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (Bone pain) and FATIGUE (Fatigue) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059E21A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Aug-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Aug-2021, the patient experienced BONE PAIN (Bone pain) and FATIGUE (Fatigue). At the time of the report, BONE PAIN (Bone pain) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medication was  provided.  No treatment  medication was  provided.   Reporter did not allow further contact
The pt experienced purple and yellow bruise, swelling 2" in diameter at the injection site. Some edema on chest side over breast and in arm.
Narrative:  Patient received two doses of Pfizer COVID 19 vaccine in April 2021. The patient tested positive for COVID 19 on 5 August 2021. The patient was hospitalized with COVID pneumonia on 17 Aug 21. The patient died due to septic and cardiogenic shock due from COVID pneumonia. The EUA requires that any patient that receives the vaccine and is diagnosed with COVID 19 that results in hospitalization or death must be reported.
noticed lumps in groin area 2MAY93; took to MD 3MAY93; 6MAY93 noticed some lumps behind ear; pt fussy & cried very hard for about 15 mins; mom gave APAP; woke up Firday eve about 11PM another crying episode;
Is excessive sweating; hot flashes; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Is excessive sweating) and HOT FLUSH (hot flashes) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Is excessive sweating) and HOT FLUSH (hot flashes). At the time of the report, HYPERHIDROSIS (Is excessive sweating) and HOT FLUSH (hot flashes) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications provided. No treatment information provided.
Number of lesions were moderate (50-500). Per 60 day follow up report-Since he had varicella menigo encephalitis his long term outlook is uncertain at this time. The Varicella was a wild virus (not vaccine strain) so adverse event was failure to protect.
Pt's shots given at 12:30p. Reaction to Hib at 12:45. Reddened welt on L thigh injection site measuring 2.25cm x 6cm. No other s/s. Pt released to home at 13:00. At 14;38 mother was called for report on pt's progress. pt resting well and symptoms nearly resolved. She started pt had reaction in the past with 1st DTaP. She was given and reaction then was gradual onset. 1st DTaP was given 7/25/01.
Patient developed hives, generalized. Given Diphenhydramine then after 4 days started on Prednisone and famotidin
exposure during pregnancy; This spontaneous retrospective pregnancy case was reported by a physician (subsequently medically confirmed) and describes the occurrence of EXPOSURE DURING PREGNANCY (exposure during pregnancy) in a 31-year-old female patient (gravida 1, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012L20A and 030ML0A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to dosage form. The patient's last menstrual period was on 08-Oct-2020 and the estimated date of delivery was 16-Jul-2021. On 15-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fourteenth week of the pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Ultrasound scan: (normal) Normal. In December 2021, Blood test: (Inconclusive) not provided.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant products was npt provided by the reporter.  Action taken with mRNA-1273 is not applicable.; Sender's Comments: This case concerns a 31-Year-old female, Para1 gravida 2, who received mRNA-1273 while pregnant (vaccine exposure during pregnancy) The patient's last menstrual period was 08-Oct-2020 a, estimated date of conception was 15-Oct-2020 and estimated due date is 16-Jul-2021. the event of vaccine exposure during pregnancy is assessed as not applicable
Patient got PREVNAR 13 inj on 10-22-15, on 10-28-15, patient stated she has redness and pain below area of injection site. Area is warm to touch and has spread. Diagnosed with cellulitis and treated with KEFLEX 250 mg 1 capsule, PO, 4 x day for 10 days, on Nov 2nd patient states symptoms have resolved. (No fever). (localised redness).
could not sleep; shakes; aches, top of the bottom all the body; headache, persistent headache; chills; This spontaneous case was reported by a consumer and describes the occurrence of INSOMNIA (could not sleep), TREMOR (shakes), MYALGIA (aches, top of the bottom all the body), HEADACHE (headache, persistent headache) and CHILLS (chills) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     Concomitant products included VITAMIN D3, MULTIVITAMIN [VITAMINS NOS], ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), ALLOPURINOL, NIFEDIPINE, OMEPRAZOLE, ATORVASTATIN, VITAMIN B COMPLEX and ASCORBIC ACID (VIT C) for an unknown indication.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INSOMNIA (could not sleep), TREMOR (shakes), MYALGIA (aches, top of the bottom all the body), HEADACHE (headache, persistent headache) and CHILLS (chills). At the time of the report, INSOMNIA (could not sleep), TREMOR (shakes), MYALGIA (aches, top of the bottom all the body) and CHILLS (chills) had resolved and HEADACHE (headache, persistent headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were reported.
Patient and parent came to the store requesting the Moderna vaccine be given to the patient. Pharmacist failed to note patient was not yet 18 and administered the vaccine. Patient had no immediate adverse events and came in for his 2nd dose (Pfizer) on 2/19/2022. At the time, the patient and mother reported patient had no adverse events following vaccination with Moderna. When the vaccine error was brought to the pharmacist's attention, the patient's mother was contacted for follow up once more, and the mother stated the patient had no adverse events.